GP
HRTX icon

GLG Partners’s Heron Therapeutics HRTX Stock Holding History

GLG Partners’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-30,643
Closed -$255K – 431
2014
Q3 		$255K Sell
30,643
-28,647
-48% -$267K 0.01% 388
2014
Q2 		$730K Sell
59,290
-66,892
-53% -$799K 0.02% 329
2014
Q1 		$1.75M Buy
+126,182
New +$1.69M 0.03% 270

Other funds holding HRTX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

GLG Partners's HRTX Position: Q4 2014 in Review

GLG Partners sold out of Heron Therapeutics (HRTX) in Q4 2014, closing a stake of 30,643 shares — an estimated $255K sold.

GLG Partners first reported a position in HRTX in Q1 2014 and held it in 3 quarters. The position peaked at $1.75M in Q1 2014. 64 funds tracked by Wall St. Rank hold HRTX as of Q4 2014.

  • GLG Partners reported no remaining Heron Therapeutics position as of Q4 2014 after selling out during the quarter.
  • GLG Partners sold 30,643 Heron Therapeutics shares in Q4 2014, an estimated $255K.
  • GLG Partners first reported a position in Heron Therapeutics in Q1 2014 and held it in 3 quarters.
  • GLG Partners's Heron Therapeutics position peaked at $1.75M in Q1 2014.
  • 64 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2014.

Based on GLG Partners's 13F filing for Q4 2014, filed 17 Feb 2015.